Parma, January 27th 2021 – The Chiesi Group’s new innovative and sustainable “home” is finally ready. The head office is situated on the outskirts of the city of Parma opposite the Research Centre, which was inaugurated in 2011, and houses around 540 people working for the Group’s executive offices, currently operating with affiliates in 30 countries worldwide.
Covering an area of 46,300 square metres – and requalifying a disused industrial estate rather than using valuable agricultural land – the new Chiesi Headquarters represents the first step towards a virtuous programme introduced by the company at all its affiliates in Italy and the rest of the world. The Better Building Programme focusses on improving sustainability at the company’s offices and plants, whilst also promoting the wellbeing of people and the community and safeguarding the planet.
In the final evaluation phase, Chiesi was also officially recognised as the largest international pharmaceutical group to achieve B Corp certification and as such, a company promoting an innovative model for doing business. This enabled it to obtain LEED Platinum certification, which is the highest level of the Leadership in Energy and Environmental Design international rating system promoted by the Green Building Council and issued by the U.S. body GBCI (Green Business Certification Inc.).
As a building in the LEED BD+C v.4 New Construction category, the Headquarters is the first of its kind to achieve Platinum level in Italy and is among the top 35 buildings in the world. In addition, the Group’s Research Centre obtained LEED Gold certification in early January. This represents another important milestone and a symbol of the company’s concrete commitment to progressively reducing environmental impact, both in the design and construction phases. It is also a key step towards the goal of achieving Carbon Neutrality by the end of 2035, which means net zero carbon emissions well ahead of the 2050 deadline set by the Paris Agreement on climate change.
“The Group’s new headquarters are a source of great pride for all of us at the company. In such complex times, rapidly completing a facility that now enables us to look to the future with even greater innovation and internationalisation in mind, whilst still retaining our roots, is an extraordinary achievement” - explains Ugo Di Francesco, CEO at the Chiesi Group -. “As Benefit Company and certified B Corp company, Chiesi has adopted a dual-purpose business model by choosing not only to pursue its own business goals but also the development of people, communities and the environment where it operates with a view to sustainability, values that have guided our company for almost a century”.
The Chiesi headquarters, whose garden forms part of the “KilometroVerdeParma” (Parma Green Kilometre), a tree-lined area of land located next to the A1 motorway and aimed at requalifying one of the busiest stretches of road in Europe, was based on three main pillars - people, innovation and sustainability – and involved its employees in internal workshops to establish their requests, needs and expectations, which were then incorporated into the new building project following careful assessment and selection.
“The building symbolises innovation, sustainability and focus on people, three concepts that have always characterised our Group” - says Alessandro Chiesi, Chief Commercial Officer for the Chiesi Group - “Our new ‘home’ was designed to blend in with the surrounding area and local community, something which allows us to continue with our growth and development programme based on a vision of the future set to become increasingly sustainable through concrete actions”.
Lastly, the new Chiesi headquarters also received the IN/ARCH 2020 Award in the New Buildings category. The acknowledgement, assigned by Inarch (the National Institute of Architecture), is awarded to projects conveying architectonic quality, not only from a formal aesthetic standpoint but also as the outcome of a process in which the client represents a fundamental component.
About Chiesi Group
Based in Parma, Italy, Chiesi is an international research-focused pharmaceuticals and healthcare group with over 85 years’ experience, operating in 30 countries with more than 6,000 employees (Chiesi Group). To achieve its mission of improving people’s quality of life by acting responsibly towards society and the environment, the Group researches, develops and markets innovative therapeutic solutions in its three focus areas: AIR (products and services that promote respiration, from new-born to adult populations), RARE (treatment for patients with rare and ultra-rare diseases) and CARE (products and services that support specialty care and consumer-facing self-care). The Group’s Research and Development centre is based in Parma and works alongside 6 other important research and development hubs in France, the U.S., Canada, China, the UK, and Sweden to pursue its pre-clinical, clinical, and regulatory programmes. In 2018 Chiesi has changed its legal status to a Benefit Corporation, according to the law in Italy, USA and, more recently, in France, by incorporating common benefit objectives into its bylaws, to generate value for its business, for the society and the environment. Since 2019, Chiesi has been the world’s largest B Corp certified pharmaceutical group. B Corps are global leaders convinced to leverage business as a force for good. Moreover, as a Benefit Corporation, Chiesi Farmaceutici S.p.A. is required by law to report annually in a transparent way about its progress in achieving the common benefits objectives it has set forward. The Group is committed to becoming carbon neutral by the end of 2035.
Contacts for the press:
Global Communication Manager
Tel: +39 339 5897483